Aurobindo Pharma shares rise 2% as pharma major’s net profit marginally dips; check all Q4 numbers

The Hyderabad-based drug maker posted a profit after tax (PAT) of ₹907 crore in the January-March quarter of FY24.

Its total revenue from operations stood at ₹8,382 crore for the fourth quarter compared to ₹7,580 crore in the year-ago period, Aurobindo Pharma said in a regulatory filing.

Following this, shares of Aurobindo Pharma were trading 1.88% higher on the National Stock Exchange at ₹1,203.10 apiece.

For the full year ended March 31, 2025, the company said its PAT rose 10% to ₹3,484 crore against ₹3,169 crore in FY24.

The total revenue from operations rose to ₹31,724 crore last fiscal from ₹29,002 crore in 2023-24.

"We are pleased to deliver another quarter and year of all-time high sales and EBITDA, reflecting the strength of our core businesses, consistent volume-led growth, and the depth of our differentiated product portfolio," Aurobindo Pharma Vice-Chairman and MD K Nithyananda Reddy said.

The drug firm's European operations continue to perform exceptionally well, moving steadily towards the $1 billion revenue milestone, he added.

"Backed by our ongoing capacity enhancements, we remain firmly positioned to sustain our trajectory and create long-term value for our stakeholders," Reddy said.

Aurobindo Pharma's US formulations revenue increased by 13.5% year-on-year (YoY) to ₹4,072 crore, while its API revenue grew 5% YoY to ₹1,069 crore.

During the quarter, the drugmaker has received final approval for 5 ANDAs (including 2 ANDAs previously tentatively approved, now receiving the final approval) from the USFDA, it said.

The company further said that its research & development (R&D, including depreciation) spend was ₹423 crore during the quarter under review, which is 5% of revenues.

Aurobindo Pharma develops, manufactures, and commercialises a wide range of generic pharmaceuticals, branded speciality pharmaceuticals and active pharmaceutical ingredients globally in over 150 countries.